Physician profile
John Kabas
NPI 1740232461
$3,406.97
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $194 · 2021: $412 · 2022: $952 · 2023: $890 · 2024: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $944.72 | 2022-2024 | Tisseel, Preveleak, Coseal |
| Atricure, INC. | $505.81 | 2019-2023 | |
| Edwards Lifesciences Corporation | $346.46 | 2019-2022 | |
| Cvrx, INC. | $322.17 | 2022-2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $235.50 | 2021-2023 | Lifevest |
| Elutia, INC. | $218.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $206.86 | 2019-2021 | |
| Stryker Corporation | $168.56 | 2023 | Spy-Phi System |
| Abiomed | $152.78 | 2019-2023 | Impella |
| Getinge USA Sales, LLC | $96.66 | 2020 | |
| Medtronic Vascular, INC. | $87.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.74 | 2019-2020 | |
| Abbott Laboratories | $18.09 | 2019 | |
| Amgen INC. | $14.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kabas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.